The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Stryker's revenues will grow 1.9% and EPS will expand 7.7%.
The average estimate for revenue is $2.07 billion. On the bottom line, the average EPS estimate is $0.98.
Last quarter, Stryker notched revenue of $2.11 billion. GAAP reported sales were 2.9% higher than the prior-year quarter's $2.05 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.98. GAAP EPS of $0.85 for Q2 were 7.6% higher than the prior-year quarter's $0.79 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 68.2%, 40 basis points better than the prior-year quarter. Operating margin was 22.6%, 10 basis points worse than the prior-year quarter. Net margin was 15.4%, 20 basis points better than the prior-year quarter.
The full year's average estimate for revenue is $8.63 billion. The average EPS estimate is $4.09.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,454 members out of 1,486 rating the stock outperform, and 32 members rating it underperform. Among 430 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 421 give Stryker a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Stryker is outperform, with an average price target of $61.10.
- Add Stryker to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
The Top 3 Dividend Aristocrats to Watch in 2018
Big news in the coming year could send these stocks higher or threaten their payouts.
These 3 Stocks Just Raised Their Dividends
There isn't much time left for companies to get in their last payout hikes of 2017. This trio made it with only weeks to spare.
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
These stocks helped put downward pressure on the market. Find out why.